Details for Patent: 11,292,815
✉ Email this page to a colleague
Which drugs does patent 11,292,815 protect, and when does it expire?
Patent 11,292,815 protects SYFOVRE and EMPAVELI and is included in two NDAs.
This patent has forty-eight patent family members in twenty-four countries.
Summary for Patent: 11,292,815
| Title: | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
| Abstract: | In some aspects, the present invention provides compositions and methods (e.g. methods of treating, preventing, making, etc.) comprising compstatin analogs. In some embodiments, compstatin analogs comprise a linear PEG moiety having a molecular weight of 40 kDa and coupled to each of two compstatin analog moieties; wherein each compstatin analog moiety is a CA28-AEEAc-Lys moiety, the linear PEG moiety is coupled to the Lys side chain of each CA28-AEEAc-Lys moiety via a carbamate and each CA28-AEEAc-Lys moiety is Ac-Ile-Cys*-Val-(1Me)Trp-Gln-Asp-Trp-Gly-Ala-His-Arg-Cys*-Thr-[NH-CH2CH2O- CH2CH2OCH2-C(.dbd.O)]-Lys-NH2 (SEQ ID NO: 51); wherein the Cys* groups are joined by a disulfide bond. |
| Inventor(s): | Francois; Cedric (Prospect, KY), Deschatelets; Pascal (West Newton, MA) |
| Assignee: | Apellis Pharmaceuticals, Inc. (Waltham, MA) |
| Application Number: | 16/912,655 |
|
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 11,292,815
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharms | SYFOVRE | pegcetacoplan | SOLUTION;INTRAVITREAL | 217171-001 | Feb 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY INTRAVITREAL ADMINISTRATION OF PEGCETACOPLAN | ⤷ Sign Up | ||
| Apellis Pharms | EMPAVELI | pegcetacoplan | SOLUTION;SUBCUTANEOUS | 215014-001 | May 14, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF PEGCETACOPLAN | ⤷ Sign Up | ||
| Apellis Pharms | EMPAVELI | pegcetacoplan | SOLUTION;SUBCUTANEOUS | 215014-001 | May 14, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF PEGCETACOPLAN SO AS TO REDUCE THE SENSITIVITY OF CELLS TO COMPLEMENT-DEPENDENT DAMAGE | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,292,815
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3660033 | ⤷ Sign Up | 301178 | Netherlands | ⤷ Sign Up |
| European Patent Office | 3660033 | ⤷ Sign Up | PA2022010 | Lithuania | ⤷ Sign Up |
| European Patent Office | 3660033 | ⤷ Sign Up | 2022C/522 | Belgium | ⤷ Sign Up |
| European Patent Office | 3660033 | ⤷ Sign Up | CA 2022 00023 | Denmark | ⤷ Sign Up |
| European Patent Office | 3660033 | ⤷ Sign Up | LUC00265 | Luxembourg | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
